Sunday, 29 January 2017

Ambulatory Services Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 | Hexa Research

The global ambulatory services market is projected to expand at a moderate CAGR of nearly 6% over the forecast period (2016 to 2024). The industry was valued approximately USD 2200 billion in 2014. High government expenditure on ambulatory care services plays a vital role in driving market demand.
Implementation of government initiatives that support team-based primary care could positively impact the market in the years to come. Popularity of day surgery centers attributes to technological advancements and reduced hospital stays. Ambulatory services lead to cost savings due to lower hospital stay costs. Unlike conventional surgeries that require long hospital stays, non-surgical methods facilitate day surgeries. This attributes to the availability of resourceful recovery procedures.

The worldwide ambulatory services industry is categorized on the basis of types and regions. As per types, the divisions are primary care offices, outpatient departments, emergency departments, surgical specialty, medical specialty, and others. With revenues surpassing USD 400 billion, primary care offices led the overall market in 2014. Being the initial point of care, primary care has been obtaining strong government support. With substantial financial impetus, governments in a number of regions have successfully established community care centers.


Popularity of same-day surgeries and technological advancements drive the surgery specialty segment. It is anticipated to grow rapidly in the forthcoming years. A number of acquisitions have been taking place over the past couple of years in the market for surgery specialty. In 2015, Apollo Hospital acquired the Nova Medical surgical unit for around USD 24 million. Such collaborations could significantly contribute to this market segment from 2016 to 2024. Several providers of ambulatory health care operate closely with other healthcare providers & physicians to expand their worldwide reach. Tenet Healthcare and United Surgical Partners International came together in 2015 and increased the network for ambulatory healthcare units.  Geographically, the global ambulatory services market is categorized into Asia Pacific, North America, Europe, the Middle East & Africa, and Latin America. North America dominated the industry in 2014. Regional drivers are shift of geriatric patients from inpatient to outpatient care and cost savings brought about by same day surgeries. The ambulatory services market in Europe is a gradually expanding one. The region is fueled by popularity of newer types of anesthesia that cause minimal discomfort to patients. This ensures rapid recovery without hospital stays.

Asia Pacific is poised to grow at a CAGR surpassing 7% over the forecast period. Burgeoning healthcare costs because of widespread prevalence of chronic ailments is causing companies & governments take to the “outpatient” trend. China has introduced mobile apps that facilitate outpatient medical appointments & payments for the same. This app in turn brings down long waiting times.

Prominent companies operating in the worldwide ambulatory services market are Medical Facilities Corporation, Nueterra, Aspen Healthcare, Surgery Partners, and Symbion. Some of the commonly used ambulatory software are ambulatory EHR/EMR, ambulatory practice management (PM), ambulatory patient portal, and ambulatory medical billing. Electronic health records (EHRs) are central repositories for patient and patient-care related data, such as progress notes, lab orders, and medication lists. Practice management systems are repositories for administrative data, such as workflow management, appointment scheduling, and patient registration. In most ambulatory facilities, patient portals are primary methods of communication that takes place between healthcare providers and patients.


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075

Thursday, 26 January 2017

Bioreactors Market Analysis, Size, Share, Growth, Industry Trends and Forecast to 2024 | Hexa Research

The worldwide bioreactors Market is anticipated to generate revenues over USD 550 million by 2024. It will grow at a CAGR above 18% in the forecast period (2016-2024). The industry is driven by the demand for biologics and adoption of single-use bioreactors (SUBs) & hybrid bioreactors. Rising popularity of SUBs in pharmaceutical manufacturing companies is yet another key driver.

SUBs or disposable bioreactors contain disposable bags instead of cultural vessels. They face high demand from the medical sector. These reactors are adopted by pharmaceutical companies to manufacture drugs without any negotiations on their quality. These systems differ in view of flexibility and cultural medium. Commercial bioreactors include CellMarket Regular from Cellexus and HyClone SUB from Thermo Fisher Scientific.

Low functional costs of SUBs and low maintenance required for them can propel market demand from 2016 to 2024. Moreover, convenience associated with marine-microbe culturing coupled with low energy consumption by SUBs could favor these reactors. But low volume capacities of SUBs can hamper the industry. 




The worldwide Bioreactors Market is fragmented on the basis of products, cells, molecules, technologies, end-users, and regions. Products include monoclonal antibodies and recombinant proteins. Monoclonal antibodies are projected to reign owing to their efficiency in medical treatments. Yeast, bacteria, and mammalian cells are the various cells. Mammalian cells should be the most rapidly growing segment. This will be attributed to their high bio-molecular effectiveness.

Recombinant proteins, monoclonal antibodies (MAbs), gene therapy, stem cells, and vaccines are classified under molecules. MAbs are used by biologics industry to manufacture vaccines. This may augments the demand for bioreactors in the next eight years. Low investment costs of SUBs to make MAbs on a small scale can add to overall market demand.

Single use bubble column bioreactor, stirred SUBs, and wave-induced motion SUBs constitute the technologies. Wave-induced motion SUBs are likely to notice the highest growth rate till 2024. Surging growth can be attributed to their high flexibility and short lead times.

End-users in the Bioreactors Market comprise R&D departments and biopharmaceutical manufacturers. The former are sub-divided into biopharmaceutical companies, contract research organizations (CROs), and research institutes.

Regions are Asia Pacific, North America, Europe, and RoW (Rest of the World). North America & Europe would garner major shares by 2024. This will be ascribed to their key biopharmaceutical firms.

Europe is predicted to capture large shares due to biologic drug patents reaching expiry. Also, regional assistance for biologic manufacturers to produce drugs with high effectiveness should benefit the region.
Asia Pacific is likely to display significant expansion because of investment opportunities for its major biologic manufacturers. Key firms opening their manufacturing units in Latin America will benefit the region.

Key companies in the global Bioreactors Market are GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, and Sartorius Stedim Biotech S.A. They are expected to further their product portfolio and offer system flexibility.

This could make consumer segments well-acquainted with various blends of bioprocessing components. It can also help them with buying decisions. Product endorsements via commercial manufacturing to obtain the finest application solutions may augur well for the market.

Browse Related Category Market Reports @


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075

Tuesday, 24 January 2017

STD Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 | Hexa Research

The global STD (sexually transmitted disease) diagnostics market is driven by growing awareness about STDs among the masses and greater governmental initiatives. Technological developments too play a vital role in fuelling market growth. Popularity of POC (point of care) testing propels the demand for improved products, such as diagnostic devices, kits, and reagents. A number of people have multiple sexual partners which in turn raises the possibility of contracting infections. Hence, there’s the growing need for accurate & precise diagnostics solutions.

The worldwide STD diagnostics market is segmented as per types of infections, location of tests, devices, and regions. On the basis of infections, the categories are human papilloma virus (HPV), syphilis, chlamydia, vaginitis, HIV (human immunodeficiency virus), herpes simplex virus, and gonorrhea. Chlamydia, gonorrhea, and syphilis are sexually transmitted infections (STIs) caused by bacteria.


Genital warts, HPV, HIV, and hepatitis genital herpes are examples of STIs caused by viruses. These microorganisms get transmitted through semen, blood, and vaginal fluids. Chlamydia is by far the most commonly occurring sexually transmitted disease. In terms of revenues, this segment held the highest share in the overall industry. It generated revenues surpassing USD 36 billion in 2016.  However, rising cases of syphilis may contribute to more than 20% of total industry revenues over the forecast period (2016 to 2024).
Based on location of tests, the market is bifurcated into laboratory testing and point of care (PoC) testing.
Laboratory tests are carried out either in public health labs or in private/commercial labs. Unlike, PoC testing solutions, laboratory tests deliver more precise results. PoC tests (such as test kits) are a more convenient option because these deliver immediate results, but they are not always accurate. The introduction of bedside & mobile testing is a step towards enhanced healthcare. The industry for bedside & mobile testing may expand at a CAGR nearly 10% from 2016 to 2024.

According to type of device, the worldwide STD diagnostics market is segmented into thermal cyclers - PCRs, lateral flow readers, flow cytometers, differential light scattering machines, absorbance microplate reader, phone chips (microfluidics+ICT), and bench top/portable/rapid diagnostics kits. Portable/rapid diagnostics and phone chips are PoC testing devices, while the others are laboratory test devices. The thermal cyclers segment is anticipated to grow rapidly at a CAGR surpassing 8% during the forecast period. The portable PoC testing devices industry is propelled by continuous technological innovations. It may generate revenues exceeding USD 46 billion by 2024.

Geographically, the global STD diagnostics market is divided into Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. Driven by surging public awareness about STIs and the presence of a well developed system of health insurance, North America dominates the global industry. Another vital factor that positively impacts this region is the growing accessibility to FDA-approved highly advanced testing devices. As per ongoing industry trends, Asia Pacific may register a high CAGR over the forecast period and thus prove to be a lucrative market in the long run. Prominent companies operating in the worldwide STD diagnostics market are Danaher Corporation, Abbott Laboratories, BioMerieux, Roche Holdings AG, and Becton Dickinson & Company.

Recently, QuantuMDx, a U.K. based company dealing in life sciences diagnostics & tools, developed the Q-Poc. This is a highly affordable diagnostic DNA analyzer which is commonly known as the “handheld lab”. It is capable of diagnosing certain types of cancers and a number of infectious diseases (including the sexually transmitted ones). Equipped with a solar battery, the Q-Poc can analyze biological samples, for example, swabs are used to detect sexually transmitted diseases/infections.

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075

Stem Cell Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 | Hexa Research

Factors that propel the global stem cell market are exhaustive R&D in therapeutic solutions and strong government support for drug discovery & related developments. Governmental support in the form of financial assistance helps fulfill a number of unmet healthcare needs. Rising cases of chronic diseases related to the liver, kidneys, and heart is another prominent factor that increases the popularity of stem cells technology. Stem cells refer to undifferentiated cells that have the capacity to regenerate and thus perform a number of functions. The growing importance of regenerative medical treatment is expected to drive the worldwide Market over the forecast period (2016 to 2024).

The four parameters based on which the global stem cell market is categorized are: products, technologies, applications, and geographies. Product-wise, the segments are human embryonic cell, pluripotent, and adult stem. Another term that defines pluripotent stem cells is “master” cells. These cells have the capacity to create cells from all three body layers. Hence, they can produce any tissue or cell that the body has to repair itself. They are self-perpetuating, that is they can develop several copies of themselves.


Embryonic stem cells are derived from the undifferentiated inner mass of cells present in a human embryo. Adult or somatic stem cells are found throughout the body and help regenerate damaged or dying cells & tissues. Adult stem cells are by far the most extensively used ones, because the human body can easily accept these cells. Furthermore, the possibility of contamination is also quite low. This segment will continue dominating the global Stem Cell Market during the forecast period. It generated revenues exceeding USD 30 billion in 2013.

Based on technologies, the global industry is categorized into cryopreservation, cell production, expansion, and cell acquisition. The overall market was dominated by the cell acquisition segment in 2013. This is the technique of obtaining stem cells from their sources. Cell culture, cloning, and in-vitro fertilization are the different techniques of cell acquisition. Bone marrow harvesting too is an integral part of such a technique. Regenerative medicine, drug discovery, and drug development are the various application areas of the global market. Ongoing trends in medicine suggest that stem cell based treatments are gradually gaining much importance in the management of diseases, such as Huntington’s chorea and Parkinson’s disease.

Based on geographies, the global stem cell market is segmented into Europe, Asia Pacific, North America, and Rest of the World. In terms of revenue, North America holds the highest share in the overall market. The region may continue expanding robustly over the forecast period because of widespread adoption of cell based therapies and high R&D investments by the public & private sectors. Asia Pacific too may expand rapidly during the same time because of medical tourism, high disposable incomes, and surging CRO (Contract Research Organization) activities. Prominent companies that hold significant shares in the global industry are Angel Biotechnology; California Stem Cell Inc.; Bioheart; Brainstorm Cell Therapeutics; and Celgene Corporation Inc.
Stemcells Inc., a California based biopharmaceutical company focuses on the development of purified human neural stem cells (HuCNS-SCs). In November 2016, the company entered a joint collaboration with Microbot Medical Ltd., a medical device company that specializes in developing & designing transformational micro-robotic technologies. With the help of highly precise & less invasive surgical solutions, these technologies aim at bettering the quality of life of patients all across the globe.


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com


Friday, 13 January 2017

Glucose Biosensors Market Analysis, Size, Share, Growth, Industry Trends and Forecast to 2024 | Hexa Research

The worldwide glucose biosensors market size is expected to surpass USD 31 billion by 2024. It was valued about USD 15.3 billion in 2015. The high incidence of diabetes is a key factor that drives this market. Technological breakthroughs in monitoring glucose levels can spur market demand. Biosensors are devices that detect biological changes in the body and display those via electronic indicators. These changes (commonly known as analytes) could be gases, organic compounds, bacteria, and others.

Glucose biosensors can sense glucose levels within the body. They are small & minimally invasive devices that assess glucose levels in outpatient settings. Need for reliable biosensors still pose a market challenge. Alternative methods, like laboratory tests can restrict market growth. But several companies are investing in R&D (research and development) to improve the current technology.


The global Glucose Biosensors Market is segmented on the basis of types, end-users, and regions. The two types are amprometric and fluorescent. Amperometric biosensors are extensively available. They function by way of glucose oxidase. These devices combine glucose with oxygen to produce hydrogen peroxide. The electrode identifies hydrogen peroxide and accurately measures glucose levels from it.

Fluorescent biosensors are estimated to capture major market shares over the forecast period (2016-2024). These biosensors measure glucose levels by detecting sensitive proteins via the fluorescence process. Better operational life of these devices may benefit the market in the years ahead.

End-users are home care diagnostics, hospitals, and others. Others include diagnostic laboratories, research institutes, and clinical. Home care diagnostics held over 46% market shares in 2015. This segment comprises the adoption hand-held glucose meters. These devices deliver quick & efficient results and reduce the need for frequent hospital visits. ‘Hospitals’ may expand significantly over the next eight years. It could grow a 10.3% CAGR from 2015 to 2022.

Regions in the global Glucose Biosensors Market are North America, Latin America, Middle East & Africa (MEA), Asia Pacific, and Europe. North America dominated the worldwide market with nearly 37% shares in 2015. Growing cases of diabetes coupled with technological advancements in the region can boost revenues during the forecast period. Europe may be the second largest market in terms of revenue after North America.
Asia Pacific is expected to grow at a CAGR of 13% from 2015 to 2022. India & China jointly accounted for over 65% of the global diabetic base in 2013. This could benefit the worldwide market in the years ahead.

Major players in the glucose biosensor industry are LifeScan Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, and Bayer AG. These companies held over 70% of the total market shares in 2014. They focus on product development, partnerships, and collaborations for long term growth and market sustenance. For instance, LifeScan introduced a new glucose monitoring system, OneTouch Verio in 2015. It measures glucose levels via a color-coded indicator.

Mayo Clinic, Gentag, NovioSense, and Fraunhofer Institute for Microelectronic Circuits & Systems entered a collaboration to fight against type 2 diabetes, in 2015. They aim at equipping smartphones with low-cost diabetes monitoring systems. The technology thus developed may be employed in a number of diabetes applications, such as eye sensors, skin patches, long-terms implantable sensors and so on. All of these devices can be controlled via smartphones. Currently, carbon nanotubes are gaining popularity due to their exceptional physical and electrical properties. These nanotubes work well with glucose biosensors by providing support for enzyme control.
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Follow us on Linkedin : https://www.linkedin.com/company/hexa-research

Sunday, 18 December 2016

Doxorubicin Market Growth, Industry Trends and Forecasts, 2016 to 2024 - Hexa Research

Doxorubicin is an anti-cancer chemotherapy drug. It is an intravenous injection through a central or peripheral venous line. No pill form of this drug is available in the market. Doxorubicin market is expected to witness a significant growth in the developed regions due to the multiple incidences of cancer occurrence in these regions. According to World Health Organization (WHO), in 2012, 14.1 million new cancer cases were detected worldwide.
Doxorubicin is an anthracycline chemotherapy drug that slows down the growth of cancer cells which is one of the primary reasons of its demand globally.. Four most common cancers worldwide are lung cancer, prostate cancer, female breast and bowel. Doxorubicin drug provides chemotherapy treatment for all four cancers which is anticipated to drive the industry in next eight years. Early diagnosis led to the longer duration of treatment which in turn increases the demand for doxorubicin drug. Increasing effectiveness of drug therapies are contributing to the higher spending on drugs for cancer care. Moreover, various government initiatives for controlling cancer and increasing its awareness through  governmental organizations such as Cancer Prevention And Control Research Network (CPCRN )and National Cancer Institute is creating to have a positive impact on the anti-cancer drug. Increased alcohol consumption, usage of tobacco coupled with lack of physical activity and unhealthy diet are considered to be main risk factors of cancer worldwide. According to WHO estimates, the mortality rate worldwide was 8.2 billion in 2012 and is expected to rise by about 70% in the near future. Due to aforementioned reasons, anti-cancer drug market revenues are anticipated to increase in the near future.
Media is also playing an important role in spreading awareness about various diseases and related drugs. Consumer awareness of these drugs is expected to have a positive impact on the doxorubicin market. Support from non-profit organizations and regional government in UK on approval of drugs is anticipated to drive the market during the forecast period.
However, Doxorubicin therapy can cause a risk of developing leukemia and tumor lysis syndrome which can further lead to kidney failure is expected to act as a roadblock for the growth of doxorubicin market. This drug also has adverse effects and can cause skin rashes, itchy sensation, can lead patient feel short of breath, swelling of face, feeling dizzy and stomach ache. Moreover, it can cause extensive tissue damage and can develop dizziness among consumer. High treatment cost poses a challenge to this market. Also, pharmaceutical industries significantly rely on the R&D initiatives. Pharmaceutical agencies are focusing on new medicines in order to cater to the customer needs which may poses as a threat to this market in the long run.
The market can be segmented on the basis of cancer type. Doxorubicin treats number of cancers such as acute lymphoblastic leukemia, acute myeloblastic leukemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck cancer, liver cancer, kidney cancer, ovarion cancer, small cell lung cancer, thyroid cancer and transitional cell bladder cancer. Drug used for treating thyroid cancer dominated the market in the recent past on account of growing incidences of thyroid cancer especially in UK.
The U.S. dominated the market in the near past on account approval of doxorubicin products by FDA and increasing number of cancer incidences. Europe is one of the major markets owing to increasing number of deaths due to cancer. Emerging nations such as India and China are anticipated to show a substantial growth rate based on the growing population, cancer incidences and tobacco consumption. Africa is expected to observe a lower growth rate owing to lack of consumer awareness and healthcare infrastructure, and expensive medication.
Key players in this market include Pfizer Inc., Dabur Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., German Remedies Ltd., Biological E Ltd., Elder Pharmaceuticals Pvt. Ltd., Cipla Ltd., Sun Pharmaceuticals Industries Ltd., Natco Pharma Ltd., Biochem Pharmaceutical Industries Ltd., Pharmacia India Ltd., VHB Life Science Inc., Chandra Bhagat Pharma Pvt. Ltd., GLS Pharma Ltd., and Intas Laboratories Pvt. Ltd. Mergers and acquisitions in this industry is helping acquirer in building technical expertise and hold a library of patents.
In March 2015, Sun Pharmaceuticals Industries Ltd. acquired Ranbaxy Laboratories Ltd. to increase its presence in the global and domestic markets by filling therapeutic gaps in the U.S.
In February 2013, Sun Pharma’s Lipodox (doxorubicin hydrochloride liposome injection) was approved by FDA for the treatment of ovarian cancer in the patients.
Browse Related Category Market Reports@

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Follow us on Linkedin: https://www.linkedin.com/company/hexa-research

Tuesday, 13 December 2016

Craniomaxillofacial Devices Market Size, Share, Growth, Industry Analysis and Forecast to 2024 | Hexa Research

The craniomaxillofacial (CMF) devices market is estimated to grow at a CAGR over 6% during the forecast period (2016-2024). Demand for minimal invasive procedures which can heal rapidly is the primary driving factor of the market. Awareness of these surgeries by ASCFS and ISCFS will facilitate in market growth. Bigger healthcare budget, use of 3D implants in reconstructive surgery, and growing geriatric populace are other aspects favoring the market.

The global market is segmented according to products, materials, applications, and regions. Products include cranial flap fixation, MF (maxillofacial) plate and screw-fixation, bone graft substitutes, and CMF distraction. Plate and screw fixation earned over 70% market revenue shares in 2014 due to their varied use in surgeries.


Materials used are metal, bioabsorable, and alloys. Titanium alloys are used to produce cranial plates due to their low weight & non-corrosive property. Polymers such as PMMA (poly methyl methacrylate) and Medpor are used due to their biocompatible nature. Biomaterials such as PDLLA and PPEK are used in bioabsorbable devices.

Neurosurgery & ENT, orthognathic & dental, plastic surgery, and others constitute as market applications. Increasing cases of spinal disorders will bring in revenues from the neurosurgery & ENT segment. Plastic surgery will see growth in the years ahead from developed countries of Canada and U.S.

Regions covered under the market are Latin America, North America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for over 58% market revenue in 2014. Other factors supporting market growth in the region are technological developments, healthcare infrastructure, and high patient awareness.

Europe is in need of technology which can cater to plate and screw fixation, thoracic fixation, CMF bone graft substitutes, and temperomandibular joint (TMJ) replacement. This is expected to net revenues over USD 227 million in 2013. Asia Pacific will exhibit growth due to economic development and improving healthcare infrastructure.

Well-known players of the craniomaxillofacial devices market are Aesculap; Johnson & Johnson (DePuy Synthes); Boston Medical Products Inc.; and Medartis AG. Research and development of products are one of the strategies followed by players. For instance, Aesculap introduced Pro space, a osteoconductive interbody fusion method in 2015.


Browse Related Category Market Reports@

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com

Wound Gel Market Size To Reach $9.68 billion By 2033

  The global wound gel market size was valued at USD 6.05 billion in 2024 and is projected to reach USD 9.68 billion by 2033, growing at a C...